Endometriosis-Related Pelvic Pain

Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?: Not FDA-cleared for endometriosis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Какие доказательства существуют?: Tier C (investigational). One small uncontrolled case series describes pain VAS improvement; there are no randomized controlled trials. Evidence-based management per ESHRE / ACOG includes hormonal therapy (combined oral contraceptives, progestin-only pills, IUS, GnRH agonists or antagonists with add-back), laparoscopic excision of endometriotic implants (gold standard for definitive diagnosis and refractory pain), and multimodal pain management including NSAIDs, pelvic floor physical therapy, and (where indicated) cognitive behavioral therapy or specialty pelvic pain referral.
Основные риски: Bleeding from bite sites for 6 to 24 hours after detachment
Bruising and tenderness over the lower abdomen, sacrum, or inner thigh for 5 to 10 days
Local skin infection or, rarely, Aeromonas infection
Allergic reaction to leech saliva (uncommon)
Temporary worsening of pelvic pain for 1 to 3 days
Small permanent scars at bite sites
Delay or replacement of hormonal therapy or laparoscopic excision
Risk of misdiagnosis of new or worsening pathology (rupture, ovarian torsion, ectopic pregnancy)
Кому не следует это рассматривать: Patients who are pregnant or attempting conception
Patients with active pelvic infection (PID, tubo-ovarian abscess)
Patients without a confirmed diagnosis (definitive diagnosis is laparoscopic visualization)
Patients on anticoagulants, with hemophilia, or with severe anemia
Patients who have not tried evidence-based hormonal therapy
Patients with severe disease (DIE — deep infiltrating endometriosis) requiring surgical management
О чём спросить врача: Has my diagnosis been confirmed (laparoscopic visualization is the gold standard)?
Have I tried evidence-based hormonal therapy (COC, progestin-only, IUS, GnRH agonist or antagonist)?
Am I a candidate for laparoscopic excision by a specialist (excision is superior to ablation for deep disease)?
Have I had pelvic floor physical therapy?
Where exactly will leeches be placed — NEVER intravaginally?
How does this fit with my fertility goals?
What is the practitioner's experience and Aeromonas-prevention plan?
Когда срочно обратиться за медицинской помощью: Sudden severe pelvic pain with nausea, vomiting, fever, or fainting (possible ovarian torsion, ruptured cyst, or ectopic pregnancy — call 911 or go to ER)
Heavy vaginal bleeding with positive pregnancy test (possible ectopic — emergency)
Severe pelvic pain with high fever and chills (possible PID or tubo-ovarian abscess)
Bleeding from a bite site lasting more than 24 to 48 hours
Fever above 38.0 C / 100.4 F or chills
Spreading redness, warmth, pus, or red streaks (cellulitis)
Hives, throat tightness, or breathing difficulty

Что это НЕ означает

This is not FDA-cleared for endometriosis.
A single small case series does NOT establish efficacy versus hormonal therapy or laparoscopic excision.
Mechanism rationale (pelvic inflammation modulation) does NOT eliminate endometriotic implants.
Leech therapy is NEVER intravaginal — that placement is contraindicated.
Leech therapy is not a substitute for hormonal therapy, laparoscopic excision, or pelvic floor physical therapy when indicated.

Перекрёстные ссылки безопасности

Clinical Profile

Category: gynecologic
ICD-10: N80.0, N80.1, N80.2, N80.3, N80.9
Safety tier: medium

Evidence Summary

No controlled clinical trial or published case series of leech therapy for endometriosis-related chronic pelvic pain exists; any use is investigational and mechanistic only. Where attempted, leeches are placed at the sacrum, lower abdomen, and inner thigh — NEVER intravaginally. A proposed mechanism involves modulation of pelvic inflammation and central pain sensitization, but this is speculative and unproven. Hormonal management (combined oral contraceptives, GnRH analogs, progestins) and definitive laparoscopic excision remain primary. Leech therapy would be adjunctive and exploratory only.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Bahmani M et al. (2017), n=18

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Active pelvic infection
Pregnancy or attempting conception
Suspected endometrial malignancy

Related Conditions

Lactational Mastitis (Non-Suppurative)

Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.

Primary Dysmenorrhea

Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.

Chronic Pelvic Pain Syndrome (Non-Specific)

Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.

Premenstrual Syndrome (Investigational)

Investigational adjunct for moderate PMS refractory to conventional therapy; small case series only; SSRI and combined hormonal contraception remain primary.